AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Matrix metalloproteinase-23

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

O75900

UPID:

MMP23_HUMAN

Alternative names:

Femalysin; MIFR-1; Matrix metalloproteinase-21; Matrix metalloproteinase-22

Alternative UPACC:

O75900; A2AGN0; A2AGN1; O75894; O75895; Q5QPQ8; Q76P96; Q7LDM6; Q7LDM7; Q9UBR9; Q9UJK8

Background:

Matrix metalloproteinase-23, known by alternative names such as Femalysin, MIFR-1, and Matrix metalloproteinases 21 and 22, plays a crucial role as a protease. It is implicated in regulating the surface expression of potassium channels by retaining them in the endoplasmic reticulum, showcasing its significance in cellular processes.

Therapeutic significance:

Understanding the role of Matrix metalloproteinase-23 could open doors to potential therapeutic strategies. Its involvement in key cellular mechanisms highlights its potential as a target for drug discovery, aiming to modulate potassium channel activities for therapeutic benefits.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.